Stocks and Investing
Stocks and Investing
Fri, August 5, 2022
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
Jonathan Chang Maintained (BCYC) at Buy with Decreased Target to $48 on, Aug 5th, 2022
Jonathan Chang of SVB Leerink, Maintained "Bicycle Therapeutics plc" (BCYC) at Buy with Decreased Target from $69 to $48 on, Aug 5th, 2022.
Jonathan has made no other calls on BCYC in the last 4 months.
There are 5 other peers that have a rating on BCYC. Out of the 5 peers that are also analyzing BCYC, 1 agrees with Jonathan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kalpit Patel of "B. Riley Securities" Downgraded from Strong Buy to Hold and Decreased Target to $33 on, Wednesday, April 13th, 2022
These are the ratings of the 4 analyists that currently disagree with Jonathan
- Peter Lawson of "Barclays" Initiated at Buy and Held Target at $30 on, Thursday, July 28th, 2022
- William Maughan of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $60 on, Wednesday, July 6th, 2022
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $37 on, Monday, May 23rd, 2022
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, April 12th, 2022
Contributing Sources